Last edition
News about "Capvaxive"
MSD's Capvaxive Receives Singapore HSA Approval for Adults Aged 18 and Above
MSD's Capvaxive receives Singapore HSA approval for active immunisation against invasive pneumococcal disease and pneumonia caused by 21 specified serotypes in adults aged 18 and above.
Capvaxive | 30/10/2026 | By News Bureau
US FDA Approves Additional Indication for CAPVAXIVE
The US Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for children and adolescents aged 2-17 years at increased risk of pneumococcal disease, broadening protection against serious pneumococcal infections in vulnerable pediatric populations.
CAPVAXIVE | 20/06/2026 | By News Bureau | 204
Merck, known as MSD outside the United States and Canada, has reported positive results from its Phase 3 STRIDE-13 trial evaluating Capvaxive, its 21-valent pneumococcal conjugate vaccine.
Capvaxive | 12/09/2025 | By Darshana | 313
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy